TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject is scheduled for a partial small/large bowel resection of primary anastomosis or total abdominal hysterectomy (simple or radical) via laparotomy~* Subject is scheduled to receive primary postoperative pain management with intravenous (i.v.) patient-controlled analgesia (PCA) opioids~Exclusion Criteria:~* Subject is scheduled for a total colectomy, colostomy, ileostomy~* Subject has complete bowel obstruction~* Subject is currently taking opioid analgesics or has taken opioid analgesics within the prior 2 weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Broncho-Adventitial Delivery of Paclitaxel to Extend Airway Patency in Malignant Airway Obstruction Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Life expectancy of at least 12 weeks~* Adequate bone marrow, liver, and renal function~* Scheduled to undergo bronchoscopy for malignant airway obstruction as standard medical care~* Pathologically confirmed, unresectable primary or recurrent non-small cell lung cancer~* Measurable disease with obstruction into the airway~* Pathologically confirmed, unresectable primary or recurrent non-small cell lung cancer~* Patients undergo recanalization procedure of tumor during bronchoscopy~* Investigator is able to insert and deploy the Blowfish Catheter into the airway after recanalization~Exclusion Criteria:~* Second primary malignancy, except for non-melanoma skin cancer and in situ cervical cancer~* Pregnant or nursing female subjects, or female subjects of child bearing potential who refuse to take a pregnancy test prior to their enrollment in this study~* Uncontrolled infection~* Presence or recent history of any systemic disorder or conditions, such as:~  * uncontrolled hypertension~ * type 1 diabetes~ * severe pulmonary hypertension~ * acute kidney injury~ * stroke (within the last 6 month)~ * myocardial infarction (within the last 3 months)~* Individuals with neurological, mental or psychiatric disorders~* Concurrent participation in another study involving investigational drugs or investigational medical devices~* Other (non-cancer) disease not stabilized within 1 month before the Screening Visit~* Known hypersensitivity to paclitaxel, Cremophor EL, or iodinated contrast media~* Any serious, uncontrolled comorbidity or condition that an Investigator believes would interfere with the intent of the study or would make participation not in the best interest of the patient Intraoperative Exclusion Criteria~* Use of pulmonary airway stents and/or ongoing or initiation of local external beam or brachytherapy radiation~* Any intraoperative complications that per the investigator's judgment increase the risk to the patient.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ramipril and Hydrochlorothiazide Alone and in Combination for the Treatment of Essential Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Previously diagnosed, or newly diagnosed essential hypertension. Blood pressure must be within a minimum and maximum range prior to drug treatment.~Exclusion Criteria:~* Inability to discontinue all prior antihypertensive medications~* Heart failure~* History of stroke, myocardial infarction, or chest pain within 3 years, or an abnormal heart rhythm~* Liver or kidney disease~* Certain drugs used to treat other conditions like an enlarged prostate gland, or arthritis~* Allergy or reactions to certain medications used to treat high blood pressure~Other protocol-defined inclusion and exclusion criteria apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Participants legally competent to sign and give informed consent and, if appropriate, assent as required by local laws.~2. Males and females, ages 6 years and older at time of signing Informed Consent (Screening). Only subjects 18 years and older will be enrolled at sites located in the province of Québec in Canada.~3. Diagnosed with atopic dermatitis 6 months duration (3 months for children), as determined by the Investigator. Stable disease for the past 4 weeks with no significant flares in atopic dermatitis before screening.~4. Females of childbearing potential (FOCBP) must have a negative serum pregnancy test at Screening and a negative urine pregnancy test at Baseline/Day 1. In addition, sexually active FOCBP must agree to use at least one form of a highly effective or barrier method of contraception throughout the trial.~5. In good health as judged by the Investigator.~6. Subjects considered reliable and capable of adhering to the Protocol and visit schedule, according to the judgment of the Investigator.~Exclusion Criteria:~1. Subjects with any serious medical condition or clinically significant abnormality that would prevent study participation or place the subject at significant risk, as judged by the Investigator~2. Has unstable AD or any consistent requirement for high potency topical steroids.~3. Subjects who are unwilling to refrain from prolonged sun exposure and from using a tanning bed or other artificial light emitting devices (LEDs) for 4 weeks prior to Baseline/Day 1 and during the study.~4. Females who are pregnant, wishing to become pregnant during the study, or are breast-feeding.~5. Previous treatment with ARQ-151.~6. Subjects with a history of chronic alcohol or drug abuse within 6 months prior to Screening.~7. Parent(s)/legal guardian(s) who are unable to communicate, read, or understand the local language(s). Subjects who are unable to communicate, read or understand the local language, or who display another condition, which in the Investigator's opinion, makes them unsuitable for clinical study participation.~8. Subjects who are family members of the clinical study site, clinical study staff, or sponsor, or family members of enrolled subjects living in the same house.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Roflumilast Cream 0.15% (Type: EXPERIMENTAL): Participants with mild to moderate AD apply roflumilast cream 0.15% QD for 4 weeks.
- Vehicle Cream (Type: PLACEBO_COMPARATOR): Participants with mild to moderate AD applied vehicle cream QD for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: High-Dose Radiation Therapy Plus Chemotherapy in Treating Patients With Advanced Nose or Throat Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed nasopharyngeal cancer~  * Stage II-IVB~ * Newly diagnosed~* No distant metastases~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* Karnofsky 60-100%~Life expectancy~* Not specified~Hematopoietic~* WBC at least 3,000/mm\^3~* Granulocyte count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~* Hemoglobin at least 8 g/dL~Hepatic~* Bilirubin no greater than 1.5 times upper limit of normal (ULN)~* Alkaline phosphatase no greater than 2.5 times ULN~* AST no greater than 2.5 times ULN~Renal~* Creatinine no greater than 1.5 mg/dL~* Creatinine clearance at least 60 mL/min~* Calcium no greater than 11.5 mg/dL~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Medically able to tolerate a definitive course of radiotherapy and the necessary immobilization~* No other active malignancy within the past 3 years except nonmelanoma skin cancer or carcinoma in situ of the cervix~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* No prior chemotherapy for this diagnosis~* More than 3 years since other prior chemotherapy~Endocrine therapy~* Not specified~Radiotherapy~* No prior radiotherapy for this diagnosis~* More than 3 years since other prior radiotherapy~* No prior radiotherapy to the head and neck region~Surgery~* Not specified

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- High-Dose Radiation Therapy Plus Chemotherapy (Type: EXPERIMENTAL): Phase I~* Radiotherapy: Patients receive radiotherapy once daily 5 days a week for 6 weeks beginning on day 1.~* Concurrent chemotherapy: Patients receive cisplatin IV over 20-30 minutes on days 1-5 and 22-26.~* Adjuvant chemotherapy: Approximately 2-5 weeks after the completion of radiotherapy, patients receive fluorouracil IV continuously on days 1-4 and cisplatin IV over 20-30 minutes on days 1-5 and 22-26. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity. In the absence of dose-limiting toxicity in 1 whole cohort of patients, study proceeds to phase II. Phase II~* Patients are treated as in phase I. Patients are followed every 3 months for 1 year, every 4 months for 1 year, every 6 months for 3 years, and then annually thereafter.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who met study entry criteria and completed 8-week induction treatment from Study A3921094 or A3921095~* Subjects who achieved clinical response in Study A3921094 or A3921095~* Women of childbearing potential must test negative for pregnancy prior to study enrollment~* Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures~* Evidence of a personally signed and dated informed consent document(s) indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.~Exclusion Criteria:~* Subjects who had major protocol violation (as determined by the Sponsor) in Study A3921094 or A3921095~* Presence of indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, or clinical findings suggestive of Crohn's disease~* Subjects who have had surgery for UC or in the opinion of the investigator, are likely to require surgery for UC during the study period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo Comparator (Type: PLACEBO_COMPARATOR): None
- CP-690,550 5 mg Arm (Type: EXPERIMENTAL): None
- CP-690,550 10 mg Arm (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: DDI Between BI Empagliflozin (10773) and Verapamil

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~healthy male and female subjects~Exclusion criteria:~Any relevant deviation from healthy conditions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Reference (Type: EXPERIMENTAL): single dose BI 10773
- Test (Type: ACTIVE_COMPARATOR): single dose BI 10773 + single dose verapamil

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of IBI306 in Participants With Hypercholesterolemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~1. Males and females ≥ 18 to ≤ 75 years of age~2. Diagnosis of hypercholesterolemia~3. LDL cholesterol ≥ 70 mg/dl (1.8mmol/L)~4. Very high or high cardiovascular risk~5. TG≤500 mg/dL(5.64 mmol/L)~Exclusion criteria~1. Uncontrolled hypertension~2. Uncontrolled hyperthyroidism or hypothyroidism~3. Severe renal dysfunction~4. Known sensitivity to any of the products to be administered during dosing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- IBI306 (Type: EXPERIMENTAL): IBI306 administered subcutaneously (SC)
- Placebo (Type: PLACEBO_COMPARATOR): administered subcutaneously (SC)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Observational Study to Evaluate Cardiovascular Outcomes of T2DM PatientsTreated With Gemigliptin

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female or male patients, who are ≥ 19 years, with diagnosis of T2DM~* Diabetic patients whose condition cannot be adequately controlled by on-going dietary and/or under antidibatetic treatment are decided to prescribe gemigliptin according to the physician's judgment~* Patients must be willing and able to provide written informed consent form to use of personal information as well as the guardian's contact information and the permission to contact with the guardian in case the patient cannot be contacted.~Exclusion Criteria:~* Patients with T1DM~* Patients who experienced an acute coronary syndrome (ST-elevation myocardial infarction and non- ST elevation myocardial infarction) or ischemic stroke within the last 3 months before enrolment OR patients who have been treated with dipeptidyl peptidase IV (DPP-4) inhibitors or glucagon-like peptide (GLP-1) analogues for 3 months before enrolment.~* Patients with a diagnosis of severe or end-stage heart failure (New York Heart Association class III or IV).~* Patients who are currently participating or plan to participate in any interventional clinical trial~* Patients who are not prescribed gemigliptin or with counterindications for gemigliptin~* Patients who are considered not fit for the study by physician

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Type 2 Diabetes Mellitus (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Artesunate+Sulfadoxine-Pyrimethamine for the Treatment of Uncomplicated Falciparum Malaria

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion:~* Age over six months.~* Mono-infection with P. falciparum detected by microscopy at a level of 500-150,000/µL asexual forms~* Presence of axillary or tympanic temperature ≥ 37.5 °C or oral or rectal temperature of ≥ 38 °C or history of fever during the past 24 h;~* ability to swallow oral medication;~* ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule; and~* Informed consent from the patient or from a parent or guardian in the case of children under 18 years of age.~Exclusion criteria:~* Presence of general danger signs in children aged under 5 years or signs of severe falciparum malaria according to the definitions of the World Health Organization (WHO)~* Mixed or mono-infection with another Plasmodium species detected by microscopy~* Presence of severe malnutrition (defined as a child whose growth standard is below -3 z-score, has symmetrical oedema involving at least the feet or has a mid-upper arm circumference \< 110 mm)~* Presence of febrile conditions due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhoea with dehydration) or other known underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases, HIV/AIDS);~* Regular medication, which may interfere with antimalarial pharmacokinetics;~* History of hypersensitivity reactions or contraindications to any of the study medications;~* Female over 12 years of age

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- falciparum malaria (Type: None): Febrile children (above six months of age) and non-pregnant adults with confirmed uncomplicated P. falciparum infection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Carbetocin at Elective Cesarean Delivery Part 3

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Patients planned for elective cesarean delivery under spinal anesthesia~* Patients who give written informed consent to participate~Exclusion Criteria:~* Patients who refuse to give written informed consent~* Patients who claim allergy or hypersensitivity to carbetocin or oxytocin~* Patients with conditions that predispose to uterine atony and postpartum hemorrhage such as placenta previa, multiple gestation, preeclampsia, eclampsia, macrosomia, polyhydramnios, uterine fibroids, previous history of uterine atony and postpartum bleeding, or bleeding diathesis.~* Patients with hepatic, renal, and vascular disease~* Patients requiring general anesthesia prior to the administration of the study drug.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Carbetocin 100mcg (Type: ACTIVE_COMPARATOR): Carbetocin 100mcg, once following delivery of the fetal head.
- Carbetocin 20mcg (Type: ACTIVE_COMPARATOR): Carbetocin 20mcg, once following delivery of the fetal head.
- Carbetocin 15mcg (Type: ACTIVE_COMPARATOR): Carbetocin 15mcg, once following delivery of the fetal head.
- Carbetocin 10mcg (Type: ACTIVE_COMPARATOR): Carbetocin 10mcg, following delivery of the fetal head.
- Carbetocin 5mcg (Type: ACTIVE_COMPARATOR): Carbetocin 5mcg, following delivery of the fetal head.
- Carbetocin 2mcg (Type: ACTIVE_COMPARATOR): Carbetocin 2mcg, following delivery of the fetal head.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of RO4917838 in Combination With Antipsychotic Treatment in Patients With Schizophrenia.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, 18-60 years of age;~* diagnosis of schizophrenia (based on screening tests);~* outpatients, with no hospitalization for worsening of schizophrenia within 3 months;~* medically and psychiatrically stable over prior 1 month and psychiatrically stable without symptom exacerbation within prior 3 months;~* currently taking no more than 2 antipsychotic drugs.~Exclusion Criteria:~* began a new non-medication treatment for schizophrenia or other psychiatric condition within last 3 months;~* on \>1 antidepressant, or a change in dose of antidepressant within 3 months;~* alcohol or substance abuse or dependence within 3 months;~* has previously received RO4917838.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- 3 (Type: EXPERIMENTAL): None
- 4 (Type: PLACEBO_COMPARATOR): None
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete